6 results
10-K
2019 FY
ARCT
Arcturus Therapeutics Holdings Inc
16 Mar 20
Annual report
11:09am
a potential vaccine for COVID-19. We continue to innovate to achieve a competitive advantage in LUNAR delivery of DNA-based and STARR-based vaccines. LUNAR … , a potential vaccine to address the Coronavirus outbreak.
Develop a competitive advantage over other nucleic acid medicine companies by continuing to innovate
S-4/A
Arcturus Therapeutics Holdings, Inc.
11 Apr 19
Registration of securities issued in business combination transactions (amended)
5:26pm
with tolerability issues present in other lipid-mediated RNA medicine delivery platforms. Our experienced team continues to innovate in the area … medicines, and externally for other nucleic acid modalities, for patients with debilitating rare diseases.
Continue to innovate in our core areas
424B3
Arcturus Therapeutics Holdings, Inc.
12 Apr 19
Prospectus supplement
4:39pm
to innovate in the area of producing LUNAR lipid formulated nucleic acid medicines in a scalable and highly-reproducible manner, reducing the costs … to innovate in our core areas of research, including mRNA design and siRNA design, LUNAR lipid formulations and formulation production to increase our
- Prev
- 1
- Next